471 related articles for article (PubMed ID: 26041736)
41. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
[TBL] [Abstract][Full Text] [Related]
42. Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy.
Iga N; Otsuka A; Hirata M; Kataoka TR; Irie H; Nakashima C; Matsushita S; Uchi H; Yamamoto Y; Funakoshi T; Fujisawa Y; Yoshino K; Fujimura T; Hata H; Ishida Y; Kabashima K
Cancer Sci; 2019 Nov; 110(11):3434-3441. PubMed ID: 31509303
[TBL] [Abstract][Full Text] [Related]
43. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
[TBL] [Abstract][Full Text] [Related]
44. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
Front Immunol; 2021; 12():623639. PubMed ID: 33692796
[TBL] [Abstract][Full Text] [Related]
45. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.
Zheng X; Koropatnick J; Chen D; Velenosi T; Ling H; Zhang X; Jiang N; Navarro B; Ichim TE; Urquhart B; Min W
Int J Cancer; 2013 Feb; 132(4):967-77. PubMed ID: 22870862
[TBL] [Abstract][Full Text] [Related]
46. Steady state dendritic cells with forced IDO expression induce skin allograft tolerance by upregulation of regulatory T cells.
Yu G; Fang M; Gong M; Liu L; Zhong J; Feng W; Xiong P; Wang CY; Gong F
Transpl Immunol; 2008 Jan; 18(3):208-19. PubMed ID: 18047928
[TBL] [Abstract][Full Text] [Related]
47. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
48. MicroRNA-214 induces dendritic cell switching from tolerance to immunity by targeting β-Catenin signaling.
Gu C; Zhou XD; Yuan Y; Miao XH; Liu Y; Ru YW; Li KQ; Li G
Int J Clin Exp Pathol; 2015; 8(9):10050-60. PubMed ID: 26617712
[TBL] [Abstract][Full Text] [Related]
49. STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.
Lemos H; Mohamed E; Huang L; Ou R; Pacholczyk G; Arbab AS; Munn D; Mellor AL
Cancer Res; 2016 Apr; 76(8):2076-81. PubMed ID: 26964621
[TBL] [Abstract][Full Text] [Related]
50. Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes.
Belladonna ML; Puccetti P; Orabona C; Fallarino F; Vacca C; Volpi C; Gizzi S; Pallotta MT; Fioretti MC; Grohmann U
Transplantation; 2007 Jul; 84(1 Suppl):S17-20. PubMed ID: 17632406
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models.
Bianco NR; Kim SH; Ruffner MA; Robbins PD
Arthritis Rheum; 2009 Feb; 60(2):380-9. PubMed ID: 19180475
[TBL] [Abstract][Full Text] [Related]
52. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
[TBL] [Abstract][Full Text] [Related]
53. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.
Munn DH; Sharma MD; Hou D; Baban B; Lee JR; Antonia SJ; Messina JL; Chandler P; Koni PA; Mellor AL
J Clin Invest; 2004 Jul; 114(2):280-90. PubMed ID: 15254595
[TBL] [Abstract][Full Text] [Related]
54. Indoleamine 2,3-dioxygenase: from catalyst to signaling function.
Fallarino F; Grohmann U; Puccetti P
Eur J Immunol; 2012 Aug; 42(8):1932-7. PubMed ID: 22865044
[TBL] [Abstract][Full Text] [Related]
55. Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway.
Li XL; Li H; Zhang M; Xu H; Yue LT; Zhang XX; Wang S; Wang CC; Li YB; Dou YC; Duan RS
J Neuroinflammation; 2016 Jan; 13():8. PubMed ID: 26757900
[TBL] [Abstract][Full Text] [Related]
56. TGF-β inhibitor Smad7 regulates dendritic cell-induced autoimmunity.
Lukas D; Yogev N; Kel JM; Regen T; Mufazalov IA; Tang Y; Wanke F; Reizis B; Müller W; Kurschus FC; Prinz M; Kleiter I; Clausen BE; Waisman A
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1480-E1489. PubMed ID: 28167776
[TBL] [Abstract][Full Text] [Related]
57. Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
[TBL] [Abstract][Full Text] [Related]
58. GDF15 Regulates Malat-1 Circular RNA and Inactivates NFκB Signaling Leading to Immune Tolerogenic DCs for Preventing Alloimmune Rejection in Heart Transplantation.
Zhang Y; Zhang G; Liu Y; Chen R; Zhao D; McAlister V; Mele T; Liu K; Zheng X
Front Immunol; 2018; 9():2407. PubMed ID: 30425709
[TBL] [Abstract][Full Text] [Related]
59. The immunoregulatory role of IDO-producing human dendritic cells revisited.
Terness P; Chuang JJ; Opelz G
Trends Immunol; 2006 Feb; 27(2):68-73. PubMed ID: 16406698
[TBL] [Abstract][Full Text] [Related]
60. Wnt5a and Wnt11 inhibit the canonical Wnt pathway and promote cardiac progenitor development via the Caspase-dependent degradation of AKT.
Bisson JA; Mills B; Paul Helt JC; Zwaka TP; Cohen ED
Dev Biol; 2015 Feb; 398(1):80-96. PubMed ID: 25482987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
